-

MedinCell Secures €10.9 Million Non-Dilutive Financing

MONTPELLIER, France--(BUSINESS WIRE)--MedinCell (Paris:MEDCL):

€10.9 million loan to increase the Company's financial visibility

Loan taken out with Banque Populaire du Sud and BNP Paribas in the form of PGE

Annual results for the FY ended March 31, 2020 will be published on June 4, 2020, after market close. As a reminder, a dedicated videoconference will be held at this occasion on Thursday, June 4:

  • 6.30 pm CEST – Presentation and Q&A in French
  • 7.30 pm CEST – Presentation and Q&A in English
  • Link to connect (only via internet): invest.medincell.com/conference

"We have maintained all operations related to strategic research and development programs since the beginning of the Coronavirus crisis, but other activities have been delayed," said Jaime Arango, Chief Financial Officer of MedinCell.

"Thanks to our partner banks who quickly mobilized to grant us this loan, we will be able to gradually return to normal activity level and advance as quickly as possible our Covid-19 program, which aims to develop a preventive treatment against the virus (prophylaxis)."

"The second half of the year should be rich for MedinCell, with potential milestones for several products based on our BEPO® technology currently in clinical studies. "

The loan is structured as a PGE (State Guaranteed Loan) with an initial maturity of 12 months at a 0,25% rate and an option for up to 5 years extension.

Contacts

MedinCell
David Heuzé
Communication leader
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier
Relation investisseurs
medincell@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Nicolas Merigeau
Relations médias
medincell@newcap.eu
+33 (0)1 44 71 94 98

MedinCell

BOURSE:MEDCL

Release Versions

Contacts

MedinCell
David Heuzé
Communication leader
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier
Relation investisseurs
medincell@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Nicolas Merigeau
Relations médias
medincell@newcap.eu
+33 (0)1 44 71 94 98

More News From MedinCell

Medincell Announces Successful c. €48 Million Private Placement

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, Australia, South Africa, Canada or Japan Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the "Company"), today announced the successful pricing of its Private Placement (as defined below) for a total amoun...

Medincell Launches a Private Placement for International Institutional Investors

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the “Company”), today announced the launch of a private placement of approximately 6% of the Company’s share capital...

Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced its participation to the 2026 Leerink Global Healthcare Conference and Jefferies Biotech on the Beach Summit in Miami, Florida, March 8 – 11, 2026. Meetings with Christophe Douat, Chief Executive Officer, and Dr Grace Kim, Chief Strategy Officer, U.S. Finance, may be arranged v...
Back to Newsroom